These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2030 related articles for article (PubMed ID: 21814200)

  • 1. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
    Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
    Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
    Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
    Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
    Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET inhibitor resistance emerges from leukaemia stem cells.
    Fong CY; Gilan O; Lam EY; Rubin AF; Ftouni S; Tyler D; Stanley K; Sinha D; Yeh P; Morison J; Giotopoulos G; Lugo D; Jeffrey P; Lee SC; Carpenter C; Gregory R; Ramsay RG; Lane SW; Abdel-Wahab O; Kouzarides T; Johnstone RW; Dawson SJ; Huntly BJ; Prinjha RK; Papenfuss AT; Dawson MA
    Nature; 2015 Sep; 525(7570):538-42. PubMed ID: 26367796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
    Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
    Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
    Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.
    Wan L; Wen H; Li Y; Lyu J; Xi Y; Hoshii T; Joseph JK; Wang X; Loh YE; Erb MA; Souza AL; Bradner JE; Shen L; Li W; Li H; Allis CD; Armstrong SA; Shi X
    Nature; 2017 Mar; 543(7644):265-269. PubMed ID: 28241141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
    Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
    Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
    Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
    Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
    Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
    J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
    Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
    Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain-containing protein 4 regulates a cascade of lipid-accumulation-related genes at the transcriptional level in the 3T3-L1 white adipocyte-like cell line.
    Mochizuki K; Yamada M; Inoue T; Hariya N; Kubota T; Goda T
    Eur J Pharmacol; 2020 Sep; 883():173351. PubMed ID: 32650006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.
    Zhou Y; Zhou J; Lu X; Tan TZ; Chng WJ
    BMC Cancer; 2018 Jul; 18(1):731. PubMed ID: 29996811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 102.